Using T1rho MRI to examine healthy brain structures
Quantitative T1rho Magnetic Resonance Imaging in Healthy Subjects
This study is testing a new type of MRI to see what healthy brain structures look like in order to help with future brain imaging.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT04993196 on ClinicalTrials.gov |
What this trial studies
This study focuses on T1rho magnetic resonance imaging, a novel MRI technique that offers high spatial resolution without the need for contrast agents. The aim is to characterize the normal appearance of T1rho values in the brain parenchyma of healthy participants. By measuring these values in normal brain structures, the study seeks to establish a baseline for future neuroimaging applications. The study involves healthy volunteers aged 18 and older who meet specific eligibility criteria.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy male and female volunteers aged 18 years and older.
Not a fit: Patients with contraindications to MRI, such as those with metallic implants or severe claustrophobia, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding of brain imaging techniques and improve diagnostic capabilities in neuroimaging.
How similar studies have performed: While T1rho imaging is a relatively novel approach, similar imaging techniques have shown promise in neuroimaging, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Male and female volunteers greater than or equal to 18 years of age Exclusion Criteria: * Subjects with a contraindication to magnetic resonance imaging such as the presence of metallic implants, claustrophobia and pregnancy. * Subjects with previous severe allergic or anaphylactoid reaction to a gadolinium contrast agent, or contraindication to contrast gadolinium administration, such severe renal disease or acutely deteriorating renal function, who would be at risk of nephrogenic systemic fibrosis * Subjects who are unable to tolerate the scan without moving the head as a result of symptoms such as tremor, spasticity, involuntary movements and spasms, cognitive impairment, coughing, and shortness of breath.
Where this trial is running
Hong Kong
- Cuhk — Hong Kong, Hong Kong (Recruiting)
Study contacts
- Study coordinator: Tiffany So
- Email: tiffanyso@cuhk.edu.hk
- Phone: +85235051035
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.